Medtronic Q1 EPS beats at $1.45; analysts raise price targets
Medtronic (MDT) reported Q1 fiscal 2027 adjusted EPS of $1.45, beating estimates by 4.32%. Sales reached $9.756B, up 13.73% YoY. Analysts raised price targets. The company increased its fiscal 2027 guidance and announced strategic investments in robotics and structural heart technologies. Shares rose 1.86% in early trading.
How this was made
The 30-second read
Why it matters
The earnings beat and raised outlook are likely to drive short-term price appreciation.
Market read
High relevance for traders focused on medtech and healthcare equities.
What to watch
Potential supply chain or regulatory risks in new robotics investments.
Background
Medtronic's Q1 earnings beat and guidance raise are the first report of these figures.
Ticker impact
Medtronic reported Q1 FY2027 EPS of $1.45 beating estimates and raised FY2027 earnings guidance.
Potential short-term rally as analysts lift price targets.
Beat on earnings and revenue, higher guidance, and analyst target raises indicate bullish sentiment.
Market effects
Medical technology sector may see broader optimism from Medtronic's beat.
U.S. healthcare stocks could benefit.
Limited to Medtronic and related medtech peers.
Counterpoint
If guidance misses future quarters, the rally could be short-lived.
Key entities
- CompanyMedtronic
Medical technology giant reporting earnings.
